Sarcopenia, sarcopenic obesity and osteoarthritis

Authors

DOI:

https://doi.org/10.15674/0030-598720213101-106

Keywords:

osteoarthritis, lean mass, quality of life

Abstract

Sarcopenia is considered an important geriatric syndrome, the manifestations of which lead to impaired quality of life and increased mortality. Sarcopenia is a disease associated with decreased muscle mass and strength. Sarcopenic obesity is manifested by an increase in subcutaneous or visceral fat, fatty degeneration of muscles, and is also accompanied by impaired muscle function. After the age of 40, an average of 8 % loss of muscle mass is noted, and by the age of 80 this value can reach 50 %. The review examined the relationship between sarcopenia, sarcopenic obesity, and osteoarthritis (OA).
Many exogenous and endogenous factors influence the development and course of OA. Based on the study of mechanisms of cellular and molecular profiles, the specific features for these frequently coexisting pathologies have been identified. The review presents the molecular mechanisms in the development of sarcopenia, sarcopenic obesity and osteoarthritis. Increased fat mass is manifested by increased adipogenesis, expression of inflammatory molecules (leptin, adiponectin, interleukin-1 (IL-1), IL-1b, IL-6 and tumor necrosis factor α) that contribute to chronic low-grade systemic inflammation
and negatively affect muscle and joint quality. The relationship between elevated levels of myostatin and muscle weakness as well as myostatin  accumulation in synovial fluid and severity of osteoarthritis was considered. Some common mechanisms in the development of sarcopenia and OA were noted: the influence of oxidative stress, systemic chronic inflammation, and disruption of the signaling pathway of bone morphogenetic proteins. Based on the analysis of associations between sarcopenia, sarcopenic obesity, and OA, population-based studies have revealed a high prevalence of knee OA with an increased risk among men with sarcopenic obesity. Women with sarcopenia and sarcopenic obesity had a high risk of knee OA in both groups. The review reviewed the prevention and treatment of the combined pathology, in particular the effect of sarcopenia on the results of total joint а rthroplasty in patients with OA. In general, sarcopenia, sarcopenic obesity, and OA can be considered as concomitant age-associated diseases that jointly affect quality of life and life expectancy.

Author Biographies

Ninel Dedukh, SI «D. F. Chebotarev Institute of Gerontology National Academy of Medical Sciences of Ukraine», Kyiv

Dr. Biol. Sci., Prof.

Nataliia Zaverukha, SI «D. F. Chebotarev Institute of Gerontology National Academy of Medical Sciences of Ukraine», Kyiv

MD

Maryna Bystrytska, SI «D. F. Chebotarev Institute of Gerontology National Academy of Medical Sciences of Ukraine», Kyiv

MD

Nataliya Yakovenchuk, Sumy Regional Clinical Hospital. Ukraine

MD

References

  1. Pickering, M., & Chapurlat, R. (2020). Where two common conditions of aging meet: Osteoarthritis and Sarcopenia. Calcified Tissue International, 107(3), 203-211. https://doi.org/10.1007/s00223-020-00703-5
  2. Bennell, K. L., Wrigley, T. V., Hunt, M. A., Lim, B., & Hinman, R. S. (2013). Update on the role of muscle in the Genesis and management of knee osteoarthritis. Rheumatic Disease Clinics of North America, 39(1), 145-176. https://doi.org/10.1016/j.rdc.2012.11.003
  3. Loureiro, A., Mills, P. M., & Barrett, R. S. (2013). Muscle weakness in hip osteoarthritis: A systematic review. Arthritis Care & Research, 65(3), 340-352. https://doi.org/10.1002/acr.21806
  4. Segal, N. A., Torner, J. C., Felson, D., Niu, J., Sharma, L., Lewis, C. E., & Nevitt, M. (2009). Effect of thigh strength on incident radiographic and symptomatic knee osteoarthritis in a longitudinal cohort. Arthritis & Rheumatism, 61(9), 1210-1217. https://doi.org/10.1002/art.24541
  5. Shorter, E., Sannicandro, A. J., Poulet, B., & Goljanek-Whysall, K. (2019). Skeletal muscle wasting and its relationship with osteoarthritis: A mini-review of mechanisms and current interventions. Current Rheumatology Reports, 21(8). https://doi.org/10.1007/s11926-019-0839-4
  6. Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., ... & Zamboni, M. (2019). Sarcopenia: Revised European consensus on definition and diagnosis. Age and Ageing, 48(4), 601-601. https://doi.org/10.1093/ageing/afz046
  7. Faulkner, J. A., Larkin, L. M., Claflin, D. R., & Brooks, S. V. (2007). Age-related changes in the structure and function of skeletal muscles. Clinical and Experimental Pharmacology and Physiology, 34(11), 1091-1096. https://doi.org/10.1111/j.1440-1681.2007.04752.x
  8. Ho, K. K., Lau, L. C., Chau, W., Poon, Q., Chung, K., & Wong, R. M. (2021). End-stage knee osteoarthritis with and without sarcopenia and the effect of knee arthroplasty – a prospective cohort study. BMC Geriatrics, 21(1). https://doi.org/10.1186/s12877-020-01929-6
  9. Tian, S., & Xu, Y. (2015). Association of sarcopenic obesity with the risk of all-cause mortality: A meta-analysis of prospective cohort studies. Geriatrics & Gerontology International, 16(2), 155-166. https://doi.org/10.1111/ggi.12579
  10. Cauley, J. A. (2015). An overview of Sarcopenic obesity. Journal of Clinical Densitometry, 18(4), 499-505. https://doi.org/10.1016/j.jocd.2015.04.013
  11. Godziuk, K., Prado, C. M., Woodhouse, L. J., & Forhan, M. (2018). The impact of sarcopenic obesity on knee and hip osteoarthritis: A scoping review. BMC Musculoskeletal Disorders, 19(1). https://doi.org/10.1186/s12891-018-2175-7
  12. Roubenoff, R. (2004). Sarcopenic obesity: The confluence of two epidemics. Obesity Research, 12(6), 887-888. https://doi.org/10.1038/oby.2004.107
  13. Chung, S. M., Hyun, M. H., Lee, E., & Seo, H. S. (2016). Novel effects of sarcopenic osteoarthritis on metabolic syndrome, insulin resistance, osteoporosis, and bone fracture: The national survey. Osteoporosis International, 27(8), 2447-2457. https://doi.org/10.1007/s00198-016-3548-0
  14. Safonova, Yu. A., & Zotkin, E. G. (219). Sarcopenia in older patients with osteoarthritis of large joints. Scientific and Practical Rheumatology, 57(2), 154–159. https://doi.org/10.14412/1995-4484-2019-154-159. [in Russian]
  15. Lovett, M., Negm, A., Ioannidis, G., Petrucelli, D., Winemaker, M., Adachi, J. D., & Papaioannou, A. (2021). Identifying patients with osteoarthritis at risk of Sarcopenia using the SARC-F. Canadian Geriatrics Journal, 24(1), 1-7. https://doi.org/10.5770/cgj.24.479
  16. Lang, T., Streeper, T., Cawthon, P., Baldwin, K., Taaffe, D. R., & Harris, T. B. (2009). Sarcopenia: Etiology, clinical consequences, intervention, and assessment. Osteoporosis International, 21(4), 543-559. https://doi.org/10.1007/s00198-009-1059-y
  17. Lee, S., Kim, T., & Kim, S. (2012). Sarcopenic obesity is more closely associated with knee osteoarthritis than is nonsarcopenic obesity: A cross-sectional study. Arthritis & Rheumatism, 64(12), 3947-3954. https://doi.org/10.1002/art.37696
  18. Haseeb, A., & Haqqi, T. M. (2013). Immunopathogenesis of osteoarthritis. Clinical Immunology, 146(3), 185-196. https://doi.org/10.1016/j.clim.2012.12.011
  19. Loeser, R. F. (2010). Age-related changes in the musculoskeletal system and the development of osteoarthritis. Clinics in Geriatric Medicine, 26(3), 371-386. https://doi.org/10.1016/j.cger.2010.03.002
  20. Bano, G., Trevisan, C., Carraro, S., Solmi, M., Luchini, C., Stubbs, B., ... & Veronese, N. (2017). Inflammation and sarcopenia: A systematic review and meta-analysis. Maturitas, 96, 10-15. https://doi.org/10.1016/j.maturitas.2016.11.006
  21. Picca, A., & Calvani, R. (2021). Molecular mechanism and pathogenesis of Sarcopenia: An overview. International Journal of Molecular Sciences, 22(6), 3032. https://doi.org/10.3390/ijms22063032
  22. Budui, S. (2015). The pathogenetic bases of sarcopenia. Clinical Cases in Mineral and Bone Metabolism, 12 (2), 22–26. https://doi.org/10.11138/ccmbm/2015.12.1.022
  23. Bolduc, J. A., Collins, J. A., & Loeser, R. F. (2019). Reactive oxygen species, aging and articular cartilage homeostasis. Free Radical Biology and Medicine, 132, 73-82. https://doi.org/10.1016/j.freeradbiomed.2018.08.038
  24. Kuszel, L., Trzeciak, T., Richter, M., & Czarny-Ratajczak, M. (2014). Osteoarthritis and telomere shortening. Journal of Applied Genetics, 56(2), 169-176. https://doi.org/10.1007/s13353-014-0251-8
  25. Ludlow, A. T., Spangenburg, E. E., Chin, E. R., Cheng, W., & Roth, S. M. (2014). Telomeres shorten in response to oxidative stress in mouse skeletal muscle fibers. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 69(7), 821-830. https://doi.org/10.1093/gerona/glt211
  26. Miller, C. J., Gounder, S. S., Kannan, S., Goutam, K., Muthusamy, V. R., Firpo, M. A., ... & Rajasekaran, N. S. (2012). Disruption of Nrf2/ARE signaling impairs antioxidant mechanisms and promotes cell degradation pathways in aged skeletal muscle. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1822(6), 1038-1050. https://doi.org/10.1016/j.bbadis.2012.02.007
  27. Scimeca, M., Piccirilli, E., Mastrangeli, F., Rao, C., Feola, M., Orlandi, A., ... & Tarantino, U. (2017). Bone morphogenetic proteins and myostatin pathways: Key mediator of human sarcopenia. Journal of Translational Medicine, 15(1). https://doi.org/10.1186/s12967-017-1143-6
  28. Zhao, C., Shao, Y., Lin, C., Zeng, C., Fang, H., Pan, J., & Cai, D. (2016). Myostatin serum concentrations are correlated with the severity of knee osteoarthritis. Journal of Clinical Laboratory Analysis, 31(5), e22094. https://doi.org/10.1002/jcla.22094
  29. Misra, D., Fielding, R. A., Felson, D. T., Niu, J., Brown, C., Nevitt, M., Lewis, C. E., Torner, J., & Neogi, T. (2019). Risk of knee osteoarthritis with obesity, Sarcopenic obesity, and Sarcopenia. Arthritis & Rheumatology, 71(2), 232-237. https://doi.org/10.1002/art.40692
  30. Vlietstra, L., Stebbings, S., Meredith-Jones, K., Abbott, J. H., Treharne, G. J., & Waters, D. L. (2019). Sarcopenia in osteoarthritis and rheumatoid arthritis: The association with self-reported fatigue, physical function and obesity. PLOS ONE, 14(6), e0217462. https://doi.org/10.1371/journal.pone.0217462
  31. Jin, W. S., Choi, E. J., Lee, S. Y., Bae, E. J., Lee, T., & Park, J. (2017). Relationships among obesity, Sarcopenia, and osteoarthritis in the elderly. Journal of Obesity & Metabolic Syndrome, 26(1), 36-44. https://doi.org/10.7570/jomes.2017.26.1.36
  32. Papalia, R., Zampogna, B., Torre, G., Lanotte, A., Vasta, S., Albo, E., Tecame, A., & Denaro, V. (2014). Sarcopenia and its relationship with osteoarthritis: Risk factor or direct consequence? Musculoskeletal Surgery, 98(1), 9-14. https://doi.org/10.1007/s12306-014-0311-6
  33. Ardeljan, A. D., Polisetty, T. S., Palmer, J., Vakharia, R. M., & Roche, M. W. (2020). Comparative analysis on the effects of Sarcopenia following primary total knee arthroplasty: A retrospective matched-control analysis. The Journal of Knee Surgery. https://doi.org/10.1055/s-0040-1713355
  34. Babu, J. M., Kalagara, S., Durand, W., Antoci, V., Deren, M. E., & Cohen, E. (2019). Sarcopenia as a risk factor for prosthetic infection after total hip or knee arthroplasty. The Journal of Arthroplasty, 34(1), 116-122. https://doi.org/10.1016/j.arth.2018.09.037
  35. Liao, C., Chen, H., Huang, S., & Liou, T. (2021). Impact of sarcopenia on rehabilitation outcomes after total knee replacement in older adults with knee osteoarthritis. Therapeutic Advances in Musculoskeletal Disease, 13, 1759720X2199850. https://doi.org/10.1177/1759720x21998508
  36. Pascual-Fernández, J., Fernández-Montero, A., Córdova-Martínez, A., Pastor, D., Martínez-Rodríguez, A., & Roche, E. (2020). Sarcopenia: Molecular pathways and potential targets for intervention. International Journal of Molecular Sciences, 21(22), 8844. https://doi.org/10.3390/ijms21228844
  37. Teng, Y., Wang, J., Chi, Y., & Tsai, T. (2020). Exercise and the Cisd2 Prolongevity gene: Two promising strategies to delay the aging of skeletal muscle. International Journal of Molecular Sciences, 21(23), 9059. https://doi.org/10.3390/ijms21239059
  38. Beaudart, C. (2018). Outcomes of the IOF-ESCEO sarcopenia working groups. WCO-IOF-ESCEO. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. Springer
  39. Zamboni, M., Rubele, S., & Rossi, A. P. (2019). Sarcopenia and obesity. Current Opinion in Clinical Nutrition & Metabolic Care, 22(1), 13-19. https://doi.org/10.1097/mco.0000000000000519

Downloads

How to Cite

Dedukh, N., Zaverukha, N., Bystrytska, M. ., & Yakovenchuk, N. (2023). Sarcopenia, sarcopenic obesity and osteoarthritis. ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS, (3), 101–106. https://doi.org/10.15674/0030-598720213101-106

Issue

No. 3 (2021)

Section

DIGESTS AND REVIEWS

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.

Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.

The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).